Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-003 in GBA1-associated Parkinson's Disease
NCT07011771Phase 2Withdrawn
- Sponsor
- Capsida Biotherapeutics
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of CAP-003 in Parkinson's disease (PD) (2 arms), sponsored by Capsida Biotherapeutics. Primary endpoint: Incidence of treatment emergent adverse events at 2 years. Planned start Aug 2025; status: withdrawn.
02
Drugs
CAP-003
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07011771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011771.